Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 16, Issue 25, Pages 2753-2764Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026616666160413141911
Keywords
HSP90; Chaperone; Inhibitor; Cancer; N-Terminal
Categories
Funding
- David Rubenstein Center for Pancreatic Cancer Research
- National Institutes of Health [1P01 CA177575-01A1]
- MSKCC Brain Tumor Center
- Susan G Komen for the Cure
Ask authors/readers for more resources
Heat shock proteins (HSPs) present as a double edged sword. While they play an important role in maintaining protein homeostasis in a normal cell, cancer cells have evolved to co-opt HSP function to promote their own survival. As a result, HSPs such as HSP90 have attracted a great deal of interest as a potential anticancer target. These efforts have resulted in over 20 distinct compounds entering clinical evaluation for the treatment of cancer. However, despite the potent anticancer activity demonstrated in preclinical models, to date no HSP90 inhibitor has obtained regulatory approval. In this review we discuss the unique challenges faced in targeting HSPs that have likely contributed to their lack of progress in the clinic and suggest ways to overcome these so that the enormous potential of these compounds to benefit patients can finally be realized. We also provide a guideline for the future development of HSP-targeted agents based on the many lessons learned during the last two decades in developing HSP90 inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available